Mutant proteins as cancer-specific biomarkers

Area of Science:

• Biochemistry
• Proteomics
• Cancer Research

Background:

• Cancer biomarkers are crucial for diagnosis, prognosis, and targeted therapy.
• Mutated gene products (proteins) are ideal biomarkers as they directly contribute to cancer development.
• Current methods for identifying these altered proteins have limitations.

Purpose of the Study:

• To demonstrate direct identification and quantification of altered proteins resulting from somatic mutations using mass spectrometry.
• To establish a method for measuring mutant protein levels in cancer cell lines and clinical specimens.
• To explore the utility of this approach for cancer diagnostics.

Main Methods:

• Utilized mass spectrometry, specifically selected reaction monitoring (SRM) with a triple-quadrupole mass spectrometer.
• Detected and quantified peptides derived from both normal and mutant alleles.
• Applied the method to quantify mutant Ras protein in cancer cell lines and clinical tumor tissues/cyst fluids.

Main Results:

• Successfully quantified mutant Ras protein molecules per cell (average 1.3 million) and the mutant-to-normal ratio (0.49–5.6).
• Detected and quantified mutant Ras proteins in colorectal and pancreatic tumor tissues.
• Identified mutant proteins in premalignant pancreatic cyst fluids.

Conclusions:

• Direct quantification of mutant proteins via mass spectrometry is feasible.
• This technique allows for precise measurement of genetically abnormal proteins in various cancer contexts.
• The approach holds significant potential for advancing cancer diagnostics and understanding tumor biology.